钙蛋白在脑胶质瘤中的表达及临床意义

Q4 Medicine

中华神经外科杂志 Pub Date : 2020-02-28 DOI:10.3760/CMA.J.ISSN.1001-2346.2020.02.005

P. Kang, Chuan-bao Zhang, Linhao Yuan, Jiayi Peng, Yangyang Wang, Wang Jia, K. Qian

{"title":"钙蛋白在脑胶质瘤中的表达及临床意义","authors":"P. Kang, Chuan-bao Zhang, Linhao Yuan, Jiayi Peng, Yangyang Wang, Wang Jia, K. Qian","doi":"10.3760/CMA.J.ISSN.1001-2346.2020.02.005","DOIUrl":null,"url":null,"abstract":"Objective \nTo detect the expression of calumenin (CALU) in human brain glioma samples, to explore its effect on the patient′s outcome, and to analyze the related biological functions of the genes co-expressed with CALU. \n \n \nMethods \nA retrospective analysis was conducted on CALU sequencing expression and clinical data of 288 glioma patients with positive CALU expression in the mRNAseq_325 database of Chinese Glioma Genome Atlas (CGGA). We analyzed the effects of CALU expression levels on survival in different types of glioma patients. The multivariate Cox regression method was used to determine the relevant factors affecting the survival of glioma patients. Pearson correlation analysis was employed to screen the related genes co-expressed with CALU and their biological functions were explored using the online bioinformatic analysis tools. \n \n \nResults \nAmong the 288 patients, the expression of CALU was 4.74±0.68, 5.49±1.12 and 6.17±0.94 in World Health Organization (WHO) grade Ⅱ, Ⅲ, and Ⅳ patients respectively, and 6.13±1.17 and 5.08±0.76 in isocitrate dehydrogenase l (IDH1) wild-type and IDH1 mutant gliomas respectively, and 5.79±0.07 and 4.71±0.07 in gliomas with 1p/19q non-codeletion and 1p/19q co-deletion. The comparative differences in the above indicators were statistically significant (all P 0.05). The median survival of CALU patients with high and low expression levels (144 cases in each) was 13.0(1-132)months and 82.5(2-149)months, respectively, which had statistically significant difference (P<0.01). In patients with WHO grade Ⅱ-Ⅳ gliomas, the high expression of CALU mainly reduced the survival time of grade Ⅲ and Ⅳ patients (both P<0.01). The multivariate Cox regression analysis showed that CALU expression was an independent factor influencing the survival of glioma patients (RR=2.193, 95%CI: 1.507-3.192, P<0.01). In the CGGA database, there were 325 genes that were positively correlated with CALU expression. The biological functions of those genes were mainly signal transduction, cell adhesion and cellular metabolism, and were mainly involved in endoplasmic reticulum protein processing, adhesion and cancer pathways. \n \n \nConclusion \nCALU is significantly related to the malignancy of brain glioma and may serve as an independent prognostic factor in high grade glioma patients, which thus provides a potential therapeutic target in the future research. \n \n \nKey words: \nGlioma; Gene expression; Prognosis; Calumenin","PeriodicalId":10100,"journal":{"name":"中华神经外科杂志","volume":"36 1","pages":"130-135"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Expression and clinical significance of calumenin in brain gliomas\",\"authors\":\"P. Kang, Chuan-bao Zhang, Linhao Yuan, Jiayi Peng, Yangyang Wang, Wang Jia, K. Qian\",\"doi\":\"10.3760/CMA.J.ISSN.1001-2346.2020.02.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo detect the expression of calumenin (CALU) in human brain glioma samples, to explore its effect on the patient′s outcome, and to analyze the related biological functions of the genes co-expressed with CALU. \\n \\n \\nMethods \\nA retrospective analysis was conducted on CALU sequencing expression and clinical data of 288 glioma patients with positive CALU expression in the mRNAseq_325 database of Chinese Glioma Genome Atlas (CGGA). We analyzed the effects of CALU expression levels on survival in different types of glioma patients. The multivariate Cox regression method was used to determine the relevant factors affecting the survival of glioma patients. Pearson correlation analysis was employed to screen the related genes co-expressed with CALU and their biological functions were explored using the online bioinformatic analysis tools. \\n \\n \\nResults \\nAmong the 288 patients, the expression of CALU was 4.74±0.68, 5.49±1.12 and 6.17±0.94 in World Health Organization (WHO) grade Ⅱ, Ⅲ, and Ⅳ patients respectively, and 6.13±1.17 and 5.08±0.76 in isocitrate dehydrogenase l (IDH1) wild-type and IDH1 mutant gliomas respectively, and 5.79±0.07 and 4.71±0.07 in gliomas with 1p/19q non-codeletion and 1p/19q co-deletion. The comparative differences in the above indicators were statistically significant (all P 0.05). The median survival of CALU patients with high and low expression levels (144 cases in each) was 13.0(1-132)months and 82.5(2-149)months, respectively, which had statistically significant difference (P<0.01). In patients with WHO grade Ⅱ-Ⅳ gliomas, the high expression of CALU mainly reduced the survival time of grade Ⅲ and Ⅳ patients (both P<0.01). The multivariate Cox regression analysis showed that CALU expression was an independent factor influencing the survival of glioma patients (RR=2.193, 95%CI: 1.507-3.192, P<0.01). In the CGGA database, there were 325 genes that were positively correlated with CALU expression. The biological functions of those genes were mainly signal transduction, cell adhesion and cellular metabolism, and were mainly involved in endoplasmic reticulum protein processing, adhesion and cancer pathways. \\n \\n \\nConclusion \\nCALU is significantly related to the malignancy of brain glioma and may serve as an independent prognostic factor in high grade glioma patients, which thus provides a potential therapeutic target in the future research. \\n \\n \\nKey words: \\nGlioma; Gene expression; Prognosis; Calumenin\",\"PeriodicalId\":10100,\"journal\":{\"name\":\"中华神经外科杂志\",\"volume\":\"36 1\",\"pages\":\"130-135\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华神经外科杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1001-2346.2020.02.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华神经外科杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1001-2346.2020.02.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

目的检测脑胶质瘤组织中钙调素（CALU）的表达，探讨其对患者预后的影响，并分析与CALU共表达基因的相关生物学功能。方法对中国胶质瘤基因组图谱mRNAseq_325数据库中288例CALU阳性胶质瘤患者的CALU序列表达及临床资料进行回顾性分析。我们分析了CALU表达水平对不同类型神经胶质瘤患者生存率的影响。采用多变量Cox回归方法确定影响胶质瘤患者生存的相关因素。采用Pearson相关分析法筛选与CALU共表达的相关基因，并利用在线生物信息学分析工具探讨其生物学功能。结果在288例患者中，世界卫生组织（世界卫生组织）Ⅱ级、Ⅲ级和Ⅳ级患者CALU的表达分别为4.74±0.68、5.49±1.12和6.17±0.94，异柠檬酸脱氢酶1（IDH1）野生型和IDH1突变型胶质瘤的CALU表达分别为6.13±1.17和5.08±0.76，1p/19q非缺失和1p/19q共缺失的胶质瘤为5.79±0.07和4.71±0.07。上述指标比较差异有统计学意义（均P＜0.05），高表达和低表达CALU患者（各144例）的中位生存期分别为13.0（1-132）个月和82.5（2-149）个月，具有统计学意义（P＜0.01），CALU的高表达主要缩短了Ⅲ级和Ⅳ级患者的生存时间（均P<0.01）。多元Cox回归分析表明，CALU的表达是影响神经胶质瘤患者生存的独立因素（RR=2.193，95%CI:1.507-3.192，P<0.01）。在CGGA数据库中，有325个基因与CALU表达呈正相关。这些基因的生物学功能主要是信号传导、细胞粘附和细胞代谢，主要参与内质网蛋白加工、粘附和癌症途径。结论CALU与脑胶质瘤的恶性程度密切相关，可能是高级别胶质瘤患者的独立预后因素，为未来的研究提供了潜在的治疗靶点。关键词：胶质瘤；基因表达；预后；Calumenin

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Expression and clinical significance of calumenin in brain gliomas

Objective To detect the expression of calumenin (CALU) in human brain glioma samples, to explore its effect on the patient′s outcome, and to analyze the related biological functions of the genes co-expressed with CALU. Methods A retrospective analysis was conducted on CALU sequencing expression and clinical data of 288 glioma patients with positive CALU expression in the mRNAseq_325 database of Chinese Glioma Genome Atlas (CGGA). We analyzed the effects of CALU expression levels on survival in different types of glioma patients. The multivariate Cox regression method was used to determine the relevant factors affecting the survival of glioma patients. Pearson correlation analysis was employed to screen the related genes co-expressed with CALU and their biological functions were explored using the online bioinformatic analysis tools. Results Among the 288 patients, the expression of CALU was 4.74±0.68, 5.49±1.12 and 6.17±0.94 in World Health Organization (WHO) grade Ⅱ, Ⅲ, and Ⅳ patients respectively, and 6.13±1.17 and 5.08±0.76 in isocitrate dehydrogenase l (IDH1) wild-type and IDH1 mutant gliomas respectively, and 5.79±0.07 and 4.71±0.07 in gliomas with 1p/19q non-codeletion and 1p/19q co-deletion. The comparative differences in the above indicators were statistically significant (all P 0.05). The median survival of CALU patients with high and low expression levels (144 cases in each) was 13.0(1-132)months and 82.5(2-149)months, respectively, which had statistically significant difference (P<0.01). In patients with WHO grade Ⅱ-Ⅳ gliomas, the high expression of CALU mainly reduced the survival time of grade Ⅲ and Ⅳ patients (both P<0.01). The multivariate Cox regression analysis showed that CALU expression was an independent factor influencing the survival of glioma patients (RR=2.193, 95%CI: 1.507-3.192, P<0.01). In the CGGA database, there were 325 genes that were positively correlated with CALU expression. The biological functions of those genes were mainly signal transduction, cell adhesion and cellular metabolism, and were mainly involved in endoplasmic reticulum protein processing, adhesion and cancer pathways. Conclusion CALU is significantly related to the malignancy of brain glioma and may serve as an independent prognostic factor in high grade glioma patients, which thus provides a potential therapeutic target in the future research. Key words: Glioma; Gene expression; Prognosis; Calumenin

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华神经外科杂志 Medicine-Surgery

CiteScore

0.10

自引率

0.00%

发文量

10706

期刊介绍： Chinese Journal of Neurosurgery is one of the series of journals organized by the Chinese Medical Association under the supervision of the China Association for Science and Technology. The journal is aimed at neurosurgeons and related researchers, and reports on the leading scientific research results and clinical experience in the field of neurosurgery, as well as the basic theoretical research closely related to neurosurgery.Chinese Journal of Neurosurgery has been included in many famous domestic search organizations, such as China Knowledge Resources Database, China Biomedical Journal Citation Database, Chinese Biomedical Journal Literature Database, China Science Citation Database, China Biomedical Literature Database, China Science and Technology Paper Citation Statistical Analysis Database, and China Science and Technology Journal Full Text Database, Wanfang Data Database of Medical Journals, etc.